Anika Therapeutics, Inc.
ANIK
$14.88
-$0.14-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 116.26M | 112.82M | 112.81M | 114.55M | 117.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 116.26M | 112.82M | 112.81M | 114.55M | 117.05M |
| Cost of Revenue | 48.14M | 49.01M | 50.45M | 48.36M | 44.74M |
| Gross Profit | 68.12M | 63.81M | 62.36M | 66.18M | 72.31M |
| SG&A Expenses | 53.95M | 49.09M | 48.33M | 50.00M | 53.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 128.52M | 123.87M | 124.60M | 123.19M | 123.33M |
| Operating Income | -12.26M | -11.05M | -11.80M | -8.64M | -6.27M |
| Income Before Tax | -10.26M | -9.31M | -10.03M | -7.47M | -4.72M |
| Income Tax Expenses | 818.00K | 672.00K | 4.23M | 5.47M | 6.11M |
| Earnings from Continuing Operations | -11.08 | -9.98 | -14.27 | -12.94 | -10.83 |
| Earnings from Discontinued Operations | 14.00K | -901.00K | -18.77M | -47.69M | -45.91M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.06M | -10.88M | -33.04M | -60.63M | -56.74M |
| EBIT | -12.26M | -11.05M | -11.80M | -8.64M | -6.27M |
| EBITDA | -6.86M | -5.47M | -6.10M | -4.22M | -1.06M |
| EPS Basic | -0.79 | -0.76 | -2.28 | -4.14 | -3.87 |
| Normalized Basic EPS | -0.46 | -0.41 | -0.41 | -0.30 | -0.18 |
| EPS Diluted | -0.80 | -0.77 | -2.29 | -4.15 | -3.88 |
| Normalized Diluted EPS | -0.46 | -0.40 | -0.41 | -0.30 | -0.18 |
| Average Basic Shares Outstanding | 56.59M | 57.35M | 57.66M | 58.01M | 58.48M |
| Average Diluted Shares Outstanding | 57.14M | 57.90M | 57.86M | 58.21M | 58.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |